ADMA Biologics (NASDAQ:ADMA – Get Free Report) and Myriad Genetics (NASDAQ:MYGN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Valuation & Earnings
This table compares ADMA Biologics and Myriad Genetics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $510.17 million | 4.71 | $146.93 million | $0.70 | 15.33 |
| Myriad Genetics | $806.60 million | 0.52 | -$365.90 million | ($1.19) | -3.66 |
ADMA Biologics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for ADMA Biologics and Myriad Genetics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 3 | 3 | 0 | 2.50 |
| Myriad Genetics | 3 | 4 | 1 | 0 | 1.75 |
ADMA Biologics presently has a consensus price target of $18.67, suggesting a potential upside of 73.97%. Myriad Genetics has a consensus price target of $4.02, suggesting a potential downside of 7.66%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, equities analysts clearly believe ADMA Biologics is more favorable than Myriad Genetics.
Risk and Volatility
ADMA Biologics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.
Profitability
This table compares ADMA Biologics and Myriad Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 32.98% | 40.17% | 26.97% |
| Myriad Genetics | -13.96% | -16.09% | -8.10% |
Institutional and Insider Ownership
75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
ADMA Biologics beats Myriad Genetics on 11 of the 14 factors compared between the two stocks.
About ADMA Biologics
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
About Myriad Genetics
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
